BTN3A2
Butyrophilin subfamily 3 member A2
Protein Summary
Plays a role in T-cell responses in the adaptive immune response. Inhibits the release of IFNG from activated T-cells. This gene encodes a member of the immunoglobulin superfamily, which resides in the juxta-telomeric region of the major histocompatability class 1 locus and is clustered with the other family members on chromosome 6. The encoded protein may be involved in the adaptive immune response. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jun 2013]
- ENST00000356386
- ENSP00000348751
- ENSG00000186470
- ENST00000377708
- ENSP00000366937
- ENST00000396934
- ENSP00000380140
- ENST00000396948
- ENSP00000380152
- ENST00000508906
- ENSP00000442687
- ENST00000527422
- ENSP00000432138
- BT3.2
- BTF3
- BTF4
- BTF4
- BT3.2
- CD277
- BTN3.2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
virus perturbation | 1 | ||
transcription factor perturbation | 0.74 | ||
histone modification site profile | 0.72 | ||
PubMedID | 0.62 | ||
tissue sample | 0.6 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 19.86 (req: < 5)
Gene RIFs: 9 (req: <= 3)
Antibodies: 107 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 19.86 (req: >= 5)
Gene RIFs: 9 (req: > 3)
Antibodies: 107 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0